NCT01091259View on ClinicalTrials.gov

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2014

Study Completion Date

May 31, 2015

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

Irinotecan

DRUG

Bevacizumab

Trial Locations (2)

10016

Bellevue Hospital Center (NYU Langone Medical Center affiliate), New York

New York University Clinical Cancer Center, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

NYU Langone Health

OTHER

NCT01091259 - Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter